[1] . Biotechnol Adv, 2003, 21(1):3-39. [2] ZHANG D L, YANG Y F, LEAKEY E A, et al. Phase Ⅰ and Phase Ⅱ enzymes produced by Cunninghamella elegans for the metabolism of xenobiotics[J] . FEMS Microbiol Lett, 1996, 138:221-226. [3] WACKETT L P, GIBSON D T. Metabolism of xenobiotic compounds by enzymes in cell extracts of the fungus Cunninghamella elegans[J] . Biochem J, 1982, 205(1):117-122. [4] HUANG H H, CHEN X Y, ZHONG D F. Selective biotransformation of propafenone by Cunninghamella blakesleana[J] . Asian J Drug Metab Pharmacokinet, 2001, 1(1):37-43. [5] WEBSTER R, PACEY M, WINCHESTER T, et al. Microbial oxidative metabolism of diclofenac:production of 4′-hydroxydiclofenac using Epiccocum nigrum IMI354292[J] . Appl Microbiol Biotechnol, 1998, 49(4):371-376. [6] KIM K A, PARK J Y. Inhibitory effect of glyburide on human cytochrome P450 isoforms in human liver microsomes[J] . Drug Metab Dispos, 2003, 31(9):1090-1092. [7] LEEMAN T, TRANSON C, DAYER P. Cytochrome P450TB (CYP2C):A major monooxygenase catalysing diclofenacs 4′-hydroxylation in human liver[J] .Life Sci, 1993, 52:29-34. [8] NAKAJIMA M, INOUE T, SHIMADA N, et al. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes[J] . Drug Metab Dispos, 1998, 26(3):261-266. [9] SCHWARZ U L. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene[J] . Eur J Clin Invest, 2003, 33(suppl 2):23-30. [10] MA G L. Metabolism study of four drugs with Cunninghamella model [D] . Shenyang：Shenyang Pharmaceutical University, 2004. [11] ZHONG D F, SUN L, LIU L, et al. Microbial transformation of naproxen by Cunninghamella species[J] . Acta Pharmacol Sin, 2003, 24(5):442-447.